Eli Lilly announced on April 20, 2026, that it has agreed to acquire Kelonia Therapeutics, a biotechnology company specializing in cancer drug development, in a deal valued at up to $7 billion [1]. The agreement includes an upfront payment of $3.25 billion, with the remaining payments contingent upon achieving clinical, regulatory, and commercial milestones. The transaction is expected to close in the second half of 2026 [1].
Kelonia is developing in vivo CAR-T technology, which enables the reprogramming of patients' T-cells inside the body to attack cancer. This approach contrasts with current ex vivo CAR-T treatments, which require harvesting and engineering cells outside the body before reintroducing them—a process that has been successful for blood cancers such as multiple myeloma but is logistically intensive [1]. According to Jacob Van Naarden, president of Lilly oncology and head of corporate business development, Kelonia's therapy is administered intravenously in a single dose, targets T-cells, and does not require preconditioning [1].
The CAR-T market has seen significant activity, with Johnson & Johnson's Carvykti generating $1.89 billion in sales last year and Gilead acquiring Arcellx and its rival CAR-T therapy for $7.8 billion [1]. Van Naarden described Kelonia's data as "nothing short of remarkable" and emphasized the potential for broader use of Kelonia's therapy beyond academic medical centers, positioning Lilly as a significant player in hematology [1].
CONCLUSION
Eli Lilly's acquisition of Kelonia Therapeutics marks a major move into the in vivo CAR-T therapy space, with a deal structure that underscores confidence in Kelonia's technology and data. The transaction is expected to strengthen Lilly's oncology portfolio and position the company competitively in the evolving cancer treatment market.